Inter-related in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: A mechanistic model supporting prevention strategies

International Journal of Oncology

Volumn 37, Issue 4, 2010, Pages 761-766

  Lin, Helen ^a   Lu, Jian Ping ^a   Laflamme, Pierre ^a   Qiao, Shengjun ^a   Shayegan, Bobby ^a   Bryskin, Inna ^c   Monardo, Lauren ^a   Wilson, Brian C ^c   Singh, Gurmit ^a,b   Pinthus, Jehonathan H ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Androgens; Fatty acids; Mitochondria; Oxidative stress; Prostate cancer prevention

Indexed keywords

ACETYLCYSTEINE; ANDROGEN; BICALUTAMIDE; CARNITINE PALMITOYLTRANSFERASE; FATTY ACID; MESSENGER RNA; METRIBOLONE; REACTIVE OXYGEN METABOLITE; ROTENONE; THENOYLTRIFLUOROACETONE;

ARTICLE; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); FATTY ACID OXIDATION; FATTY ACID TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MUTAGENESIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR;

EID: 77956542059     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000725     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
2. Fleshner NE and Klotz LH: Diet, androgens, oxidative stress and prostate cancer susceptibility. Cancer Metastasis Rev 17: 325-330, 1998.
3. Klein EA, Casey G and Silverman R: Genetic susceptibility and oxidative stress in prostate cancer: Integrated model with implications for prevention. Urology 68: 1145-1151, 2006. (Pubitemid 44880356)
4. Sung SY, Kubo H, Shigemura K, et al: Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res 66: 9519-9526, 2006.
5. Shigemura K, Sung SY, Kubo H, et al: Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Prostate 67: 722-731, 2007.
6. Pinthus JH, Bryskin I, Trachtenberg J, et al: Androgen induces adaptation to oxidative stress in prostate cancer: Implications for treatment with radiation therapy. Neoplasia 9: 68-80, 2007. (Pubitemid 46203935)
7. Ripple MO, Henry WF, Rago RP, et al: Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 89: 40-48, 1997.
8. Pinthus JH, Lu JP, Bidaisee LA, et al: Androgen-dependent regulation of medium and long chain fatty acids uptake in prostate cancer. Prostate 67: 1330-1338, 2007.
9. Swinnen JV, Esquenet M, Goossens K, Heyns W and Verhoeven G: Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCAP. Cancer Res 57: 1086-1090, 1997.
10. Tyrrell CJ, Denis L, Newling D, Soloway M, Channer K and Cockshott ID: Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex study group. Eur Urol 33: 39-53, 1998.
11. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH and Taegtmeyer H: Metabolic gene expression in fetal and failing human heart. Circulation 104: 2923-2931, 2001. (Pubitemid 33139104)
12. Nubel T and Ricquier D: Respiration under control of uncoupling proteins: Clinical perspective. Horm Res 65: 300-310, 2006.
13. Clinton SK and Giovannucci E: Diet, nutrition, and prostate cancer. Annu Rev Nutr 18: 413-440, 1998.
14. Ramon JM, Bou R, Romea S, et al: Dietary fat intake and prostate cancer risk: A case-control study in Spain. Cancer Causes Control 11: 679-685, 2000.
15. Kolonel LN, Nomura AM and Cooney RV: Dietary fat and prostate cancer: Current status. J Natl Cancer Inst 91: 414-428, 1999. (Pubitemid 29128277)
16. Warburg O: On respiratory impairment in cancer cells. Science 124: 269-270, 1956.
17. Singh G, Lakkis CL, Laucirica R and Epner DE: Regulation of prostate cancer cell division by glucose. J Cell Physiol 180: 431-438, 1999.
18. Liu Y: Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 9: 230-234, 2006. (Pubitemid 44317255)
19. Moore S, Knudsen B, True LD, et al: Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma. Int J Cancer 114: 563-571, 2005.
20. Ntambi JM, Miyazaki M, Stoehr JP, et al: Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci USA 99: 11482-11486, 2002.
21. Zha S, Ferdinandusse S, Hicks JL, et al: Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate 63: 316-323, 2005. (Pubitemid 40664342)
22. Luo J, Zha S, Gage WR, et al: Alpha-methylacyl-CoA racemase: A new molecular marker for prostate cancer. Cancer Res 62: 2220-2226, 2002.
23. Wanders RJ, Vreken P, Ferdinandusse S, et al: Peroxisomal fatty acid alpha- and beta-oxidation in humans: Enzymology, peroxisomal metabolite transporters and peroxisomal diseases. Biochem Soc Trans 29: 250-267, 2001.
24. Lloyd MD, Darley DJ, Wierzbicki AS and Threadgill MD: Alpha-methylacyl-CoA racemase-an 'obscure' metabolic enzyme takes centre stage. FEBS J 275: 1089-1102, 2008.
25. Chen W, Wu W, Zhao J, et al: Molecular cloning and preliminary analysis of the human alpha-methylacyl-CoA racemase promoter. Mol Biol Rep 36: 423-430, 2009.
26. Zha S, Ferdinandusse S, Denis S, et al: Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res 63: 7365-7376, 2003. (Pubitemid 37413478)
27. Rossi S, Graner E, Febbo P, et al: Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1: 707-715, 2003.
28. Schmidt LJ, Ballman KV and Tindall DJ: Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride. Prostate 67: 1111-1120, 2007. (Pubitemid 46983340)
29. Thompson IM, Goodman PJ, Tangen CM, et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215-224, 2003.
30. Andriole GL: Overview of pivotal studies for prostate cancer risk reduction, past and present. Urology 73: S36-S43, 2009.